


Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH

| | |
|---------------------------|--|
| Cat. No.: | HY-147090 |
| CAS No.: | 2750350-39-9 |
| Molecular Formula: | C ₃₄ H ₄₃ N ₃ O ₇ |
| Molecular Weight: | 605.72 |
| Target: | Histone Methyltransferase |
| Pathway: | Epigenetics |
| Storage: | 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 160 mg/mL (264.15 mM)
* "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
|---------------------------|--------------------------|---------------|-----------|-----------|------------|
| | | Concentration | 1 mg | 5 mg | 10 mg |
| | 1 mM | | 1.6509 mL | 8.2546 mL | 16.5093 mL |
| | 5 mM | | 0.3302 mL | 1.6509 mL | 3.3019 mL |
| | 10 mM | | 0.1651 mL | 0.8255 mL | 1.6509 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b) is an EZH2 degrader and can be used for the research of lymphoma^[1].

IC₅₀ & Target

EZH2

REFERENCES

[1]. Tu Y, et al. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. J Med Chem. 2021 Jul 22;64(14):10167-10184.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA